Cerebrovascular Disease Progression in Patients With ACTA2 Arg179 Pathogenic Variants

Arne Lauer1, Samantha L Speroni1, Jay B Patel1

  • 1From the Departments of Neurology (A.L., S.L.S., P.L.M.) and Radiology (J.B.P., J.K.-K., P.C.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Internal Medicine (E.R., D.M.M.), McGovern Medical School, University of Texas Health Science Center at Houston; Department of Neuroradiology (A.L., M.C.), Goethe University, Frankfurt am Main, Germany; andDepartment of Neurosurgery (E.S.), Boston Children's Hospital, Harvard Medical School, Boston, MA.

Neurology
|November 17, 2020
PubMed
Abstract

Insights

Patients with ACTA2 gene mutations show progressive arterial narrowing and stroke, with early white matter injury. Imaging biomarkers can track disease progression and guide stroke prevention in infants.

Area of Science:

  • Neurology
  • Genetics
  • Radiology

Background:

  • Smooth muscle dysfunction syndrome can be caused by ACTA2 gene mutations.
  • Cerebrovascular abnormalities, including stroke and arterial steno-occlusive disease, are known complications.

Purpose of the Study:

  • To establish progression of imaging biomarkers for stroke, arterial steno-occlusive disease, and white matter injury in patients with ACTA2 gene mutations.
  • To analyze cerebral MRI scans from a retrospective cohort of patients with ACTA2 Arg179 pathogenic variants.

Main Methods:

  • Systematic quantification of arterial ischemic strokes and white matter lesions using planimetric methods on baseline and follow-up MRI scans.
  • Quantification of critical stenosis and arterial vessel diameters using manual and semiautomated methods on cerebral magnetic resonance angiograms.
  • Assessment of correlations between arterial abnormalities and parenchymal injury.

Main Results:

  • Characteristic patterns of acute white matter ischemic injury and progressive internal carotid artery stenosis observed during infancy.
  • Stable white matter hyperintensities but increased cystic-like lesions over time in patients older than 1.2 years.
  • Progressive internal carotid artery narrowing (80% of patients) correlated with critical stenoses and arterial ischemic infarctions; strokes occurred in territories affected by stenosis.

Conclusions:

  • Early and progressive cerebrovascular abnormalities are characteristic of ACTA2 Arg179 pathogenic variants.
  • Steno-occlusive disease progresses, associated with infarctions and cystic white matter lesions, while white matter hyperintensities remain stable.
  • Evaluated metrics can aid early diagnosis, monitor disease progression, guide stroke prevention, and assess therapeutic responses.

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
266
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
97
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
201
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.0K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
189
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.2K